Metformin use by type 2 diabetics is associated with a lower risk of death from cardiovascular disease, according to a recent meta-analysis published in the Archives of Internal Medicine (2008;168:2070-2080).

The meta-analysis of 40 clinical trials, led by Elizabeth Selvin, PhD, MPH, of the Johns Hopkins Bloomberg School of Public Health in Baltimore, found no associations between other diabetes drugs and cardiovascular effects, in part because of insufficient data, the authors noted.